Farmas USA

Eso es!.Fallo mio :P

Para entrar ahora en AMRN tendría que salirme de alguna otra, y seguro que entonces esa empieza a subir de lo lindo...jajajaj

Un saludo y suerte con AMRN, kubatta....

No se yo si será suficiente con superar esos 5,60 para romper la tendencia claramente bajista que inició el valor en diciembre de 2012.....

Un saludo

AMRN

Al menos hoy la teneis en verde, que ya es mucho, con el día tan askeroso que tenemos....

Por cierto, el hostión de las BIOD es impresionante....de 6 a 4$....suerte que vendí a tiempo....en septiembre, presentan resultados de Fase II para el BIOD-123, una insulina de efecto rápido...

Un saludo

Ja n'he fet. Al Setembre mes. Pero no puc deixar de mirar la borsa. Es un vici. Quina ost... les ZLCS avui. Han tancat el GAP a 0,64 i s'han passat fins als 0,6... No se que dir. Un pullback potent....

ZLCS en 0,6 ya... -13%. Vaya pullback. Aunue estamos un 20% sobre minimos. Deberiamos cerrar sobre la MM200. En 0,623.... Mal lo veo...

7 millones y pico de volumen,empieza a hervir el agua,aun tenemos que echar ingredientes,cocerlo,un poco de reposo y comerlos....pero ya esta en marcha :)

AMRN es un gigante dormido.

"What other "similar" products is Wainwright talking about??

"Shares of drug maker Amarin (AMRN) are climbing after H.C. Wainwright analyst Andrew Fein upgraded the stock. WHAT'S NEW: Amarin's stock is likely to climb soon, as investors start to anticipate that the FDA will approve the company's Vascepa drug for patients with multiple lipid disorders, Fein wrote in a note to investors. Developed from omega 3 fatty acids, Vascepa reduces fat in the blood. Amarin's shares should rise towards the $8-$10 range in anticipation of a positive decision from the FDA, according to Fein, who thinks that the agency is "highly likely" to grant its approval. The agency is supposed to issue its decision on the drug in December, and an FDA panel is slated to issue a recommendation on the application in October, the analyst noted. The panel is very likely to recommend approval of Vascepa, added Fein. On the other hand, the analyst does not expect Amarin to partner with another company on Vascepa. Such a partnership would be much more beneficial for the company than FDA approval, he contended. Furthermore, Vascepa will likely have to compete with a number of similar products, the analyst wrote. Nonetheless Fein upgraded Amarin to Buy from Hold. with a $10 price target.